IQVIA, Veeva announce global clinical and commercial partnerships.

IQVIA and Veeva have announced long-term partnerships for clinical and commercial efficiency, allowing customers to use software, data, and services from both companies together. The partnerships resolve all pending legal disputes and enable seamless collaboration. The agreements cover commercial and clinical areas, providing customers with access to a range of offerings.

IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) have announced significant long-term partnerships aimed at improving clinical and commercial efficiency for their customers. The agreements resolve all pending legal disputes and enable seamless collaboration between the two companies. These partnerships provide customers with access to a wide range of software, data, and service offerings from both IQVIA and Veeva.

Under the terms of the partnership, customers can now use Veeva's software and IQVIA's data in a simplified and efficient manner. The commercial aspect of the agreement includes master data and software third-party access (TPA) agreements, allowing IQVIA or Veeva data to be used with each other's software or services. For instance, IQVIA data can be used in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI. Additionally, IQVIA has joined Veeva's Technology, AI, and Services Partner Programs to support customer integrations between Veeva software and IQVIA Analytics, IQVIA Information Management (including MDM), IQVIA Agentic AI, and IQVIA Commercial Orchestration offerings [1].

In the clinical domain, IQVIA has joined Veeva's CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products. This partnership allows customers to benefit from IQVIA's clinical data management, technology solutions, and EDC programming expertise with Veeva software to accelerate database builds, study locks, and data delivery [1].

Peter Gassner, Veeva founder and CEO, expressed enthusiasm about the potential for these partnerships, stating, "We are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall. I am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers" [1].

Ari Bousbib, chairman and CEO of IQVIA, echoed this sentiment, noting, "IQVIA and Veeva's partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients. This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients" [1].

These partnerships are timely, given the growing complexity in clinical trial methodologies and the increasing reliance on contract research organizations (CROs). The eClinical Solutions Market is estimated to reach over USD 35.0 Bn by 2034, exhibiting a CAGR of 11.8% during the forecast period [2].

References:
[1] https://www.prnewswire.com/news-releases/iqvia-and-veeva-announce-long-term-clinical-and-commercial-partnerships-and-resolution-of-all-disputes-302531726.html
[2] https://www.ainvest.com/news/mizuho-increases-icon-public-limited-company-price-target-225-maintains-outperform-rating-2508/